The Wiley Protocol Is Now Patent Protected
Ten years after the first in lab experiments with 
progesterone and breast cancer cells, seven years after the publication of Sex, Lies and Menopause and the creation of the Wiley Protocol for women, the USPTO has recognized the Wiley Protocol as unique with its recent patent ruling : The Wiley Protocol # 7,879,830.
Patented for treatment using a 28-day biomimetic, variable dose cycling bio-identical hormone therapy protocol, this ground-breaking ruling paves the way for greater standardization of compounded medicines, including standardized dose modification, which increases safety for women, and complete protection for patients who wish to utilize WP for therapy. They can now be assured they are getting the real Protocol made by trained pharmacists and dispensed by knowledgeable physicians.
It's a nod toward the unique nature, long term clinical results, and peer-reviewed science driven approach that the Wiley Protocol entails. We will continue to study BHRT in this now patent-protected environment for the good of all women. Physicians and Pharmacists who join our project can, too, now be assured of governmental co-operation to produce quantity medical care....
Sexy Forever
In Suzanne Somers new book, Sexy Forever, there was statement made in error on page 70.
To set the record straight: Estrone is a known carcinogen and is not now, nor ever was or will be an ingredient in the Wiley Protocol. And, more importantly, the estriol provided to Suzanne Somers in addition to 28WP by Dr. Wright is not condoned by T.S. Wiley. She says, "In our experience with our WIley Protocol breast cancer study and statistics, estriol has the ability to enhance tumorigenesis. " T.S. Wiley has never and will never devise a rhythmic dosing schedule for estriol, because the estradiol rhythmically dosed in the Wiley Protocol perfectly converts to adequate amounts of estriol as proven by urine tests actually used by Dr. Wright...
Why Almost Everything You Hear About Medicine Is Wrong
If you follow the news about health research, you risk whiplash. First garlic lowers bad cholesterol, then—after more study—it doesn't. Hormone replacement reduces the risk of heart disease in postmenopausal women, until a huge study finds that it doesn't (and that it raises the risk of breast cancer to boot). Eating a big breakfast cuts your total daily calories, or not—as a study released last week finds. Yet even if biomedical research can be a fickle guide, we rely on it.
But what if wrong answers aren't the exception but the rule? More and more scholars who scrutinize health research are now making that claim. It isn't just an individual study here and there that's flawed, they charge. Instead, the very framework of medical investigation may be off-kilter, leading time and again to findings that are at best unproved and at worst dangerously wrong. The result is a system that leads patients and physicians astray—spurring often costly regimens that won't help and may even harm you.
It's a disturbing view, with huge im-plications for doctors, policymakers, and health-conscious consumers. And one of its foremost advocates, Dr. John P.A. Ioannidis, has just ascended to a new, prominent platform after years of crusading against the baseless health and medical claims. As the new chief of Stanford University's Prevention Research Center, Ioannidis is cementing his role as one of medicine's top mythbusters. "People are being hurt and even dying" because of false medical claims, he says: not quackery, but errors in medical research...
The Truth Wears Off
On September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties. The drugs, sold under brand names such as Abilify, Seroquel, and Zyprexa, had been tested on schizophrenics in several large clinical trials, all of which had demonstrated a dramatic decrease in the subjects' psychiatric symptoms. As a result, second-generation antipsychotics had become one of the fastest-growing and most profitable pharmaceutical classes. By 2001, Eli Lilly's Zyprexa was generating more revenue than Prozac. It remains the company's top-selling drug.
But the data presented at the Brussels meeting made it clear that something strange was happening: the therapeutic power of the drugs appeared to be steadily waning. A recent study showed an effect that was less than half of that documented in the first trials, in the early nineteen-nineties. Many researchers began to argue that the expensive pharmaceuticals weren't any better than first-generation antipsychotics, which have been in use since the fifties. "In fact, sometimes they now look even worse," John Davis, a professor of psychiatry at the University of Illinois at Chicago, told me...
Escitalopram Linked to Significant Reduction in Menopausal Hot Flashes
Antidepressant therapy with the selective serotonin reuptake inhibitor escitalopram significantly reduced menopausal hot flash frequency and severity compared with placebo, according to the results of a new study published in the January 19 issue of the Journal of the American Medical Association.
The findings suggest "escitalopram provides a nonhormonal, off-label option that is effective and well tolerated in the management of menopausal hot flashes," lead study author Ellen W. Freeman, PhD, from the Departments of Obstetrics/Gynecology and Psychiatry at the University of Pennsylvania School of Medicine in Philadelphia, writes.
"This is particularly important for women who have risk factors for hormone therapy, although there are many other women who do not want hormone therapy because of its risks," Dr. Freeman told Medscape Medical News.
Noting that comparisons with other studies must be viewed with caution, the study authors added that escitalopram's reduction in hot flash frequency relative to placebo "was only modestly less" than what has been reported for estrogen therapy...
Breast Implants Cancer Link Found, Says FDA
Federal health officials said Wednesday they are investigating a possible link between breast implants and a very rare form of cancer, raising new questions about the safety of devices which have been scrutinized for decades.
The cancer, known as anaplastic large cell lymphoma, attacks lymph nodes and the skin and has been reported in the scar tissue which grows around an implant. The Food and Drug Administration is asking doctors to report all cases of the cancer so the agency can better understand the association.
The agency has learned of just 60 cases of the disease worldwide, among the estimated 5 million to 10 million women with breast implants. The agency reviewed the scientific literature going back to 1997 along with information provided by international governments and manufacturers.
Most of the cases were reported after patients sought medical care for pain, lumps, swelling and other problems around the surgical site...
The Wiley Protocol In Four Continents!
The Wiley Protocols are now available on four continents, North America, Asia, Australia and Europe, including 24 states.
Follow Us Daily!
Follow us at The Wiley Protocol Twitter
Join our Wiley Protocol Facebook Community
Read about our latest articles, products, news, and events at The Wiley Protocol on Digg
What Are Your Questions?
This is your newsletter and we want to hear from you. Tell us what questions and answers you would like to see addressed in the Wiley Protocol Newsletters. Write to
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Check Out This Cool Clock! Click Here!
